ArticleJournal of the American Heart Association2025
Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pathological mechanisms and therapeutic potential of MSC-Exos in ischemic stroke management.Stem cell research & therapy · 2026Review
- Qingxin Jieyu Granule Ameliorates Myocardial Ischemia/Reperfusion Injury by Inhibiting Cardiomyocyte Pyroptosis via Regulating Circulating Exosomes.Chinese journal of integrative medicine · 2026Article
- Stem Cells and Their Derivatives in Cardiac Fibrosis Therapy: Challenges and Perspectives.Cells · 2026Review
- Hydrogels loaded with different substances for treating heart failure: a promising therapy.Frontiers in cardiovascular medicine · 2026Review
- Extracellular Vesicles in the Heart-Organ Axis: From Inter-Organ Communication to Precision Nanomedicine for Heart Diseases.International journal of nanomedicine · 2026Review
- Nanoparticle-Based Therapeutic Strategies for Pathological Cardiac Hypertrophy: Preclinical Advances, Translational Challenges, and Future Perspectives.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExosomes are extracellular vesicles 30 to 150 nm in size, mediating the paracrine effects of mesenchymal stem cells (MSCs) and induced pluripotent stem cell-derived cardiomyocytes (iCMs) when used to restore the injured myocardium. While both MSC- and iCM-derived exosomes (MSC-Exo, iCM-Exo) improve cardiac function, their mechanisms of action remain incompletely understood. This study investigates the shared and distinct effects of iCM-Exo and MSC-Exo in a porcine ischemia-reperfusion injury model.
methodsFemale Yorkshire swine underwent proximal left anterior descending artery occlusion with a catheter balloon to induce ischemia-reperfusion injury. Ten 500-μL transendocardial injections delivered a total of 5×10
resultsCardiac MRI revealed that iCM-Exo significantly improved left ventricular ejection fraction, myocardial viability, scar size, and ventricular remodeling compared with MSC-Exo and PBS controls. Transcriptomic analysis revealed both shared and distinct gene expression patterns between the treatments. Shared pathways, including extracellular matrix remodeling and neurovascular integration, contributed to baseline cardiac improvement. Distinct pathways in iCM-Exo treatment involved metabolic reorganization and cardiomyocyte-specific processes, while MSC-Exo emphasized structural stabilization and anti-inflammatory responses.
conclusionsThese findings highlight the complementary roles of iCM-Exo and MSC-Exo in myocardial repair with shared pathways contributing to baseline improvement and distinct pathways driving differences in efficacy. Future studies investigating the potential of combinatorial approaches may provide further insights into optimizing the therapeutic outcomes for patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.